These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26579944)

  • 1. Organ Dose Estimates for Hyperthyroid Patients Treated with (131)I: An Update of the Thyrotoxicosis Follow-Up Study.
    Melo DR; Brill AB; Zanzonico P; Vicini P; Moroz B; Kwon D; Lamart S; Brenner A; Bouville A; Simon SL
    Radiat Res; 2015 Dec; 184(6):595-610. PubMed ID: 26579944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
    Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
    J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters.
    Huysmans DA; Buijs WC; van de Ven MT; van den Broek WJ; Kloppenborg PW; Hermus AR; Corstens FH
    J Nucl Med; 1996 Dec; 37(12):2072-9. PubMed ID: 8970537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients.
    Canzi C; Zito F; Voltini F; Reschini E; Gerundini P
    Med Phys; 2006 Aug; 33(8):2860-7. PubMed ID: 16964862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
    Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
    Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of factors affecting treatment results for toxic goiter with radioactive 131I].
    Listewnik MH
    Ann Acad Med Stetin; 2000; 46():109-21. PubMed ID: 11712298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal organ radiation dosimetry and associated uncertainties in nuclear medicine, with emphasis on iodine-131.
    Brill AB; Stabin M; Bouville A; Ron E
    Radiat Res; 2006 Jul; 166(1 Pt 2):128-40. PubMed ID: 16808602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated dose rates to members of the public from external exposure to patients with 131I thyroid treatment.
    Dewji S; Bellamy M; Hertel N; Leggett R; Sherbini S; Saba M; Eckerman K
    Med Phys; 2015 Apr; 42(4):1851-7. PubMed ID: 25832075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.
    Willegaignon J; Sapienza MT; Coura-Filho GB; Watanabe T; Traino AC; Buchpiguel CA
    Med Phys; 2014 Jan; 41(1):012503. PubMed ID: 24387527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The feasibility of low-dose oral lithium therapy and its effect on thyroidal radioiodine uptake, retention, and hormonal parameters in various subcategories of hyperthyroid patients: a pilot study.
    Chouhan A; Abhyankar A; Basu S
    Nucl Med Commun; 2016 Jan; 37(1):74-8. PubMed ID: 26465804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine therapy for Graves disease: thyroid absorbed dose of 300 Gy-tuning the target for therapy planning.
    Willegaignon J; Sapienza MT; Buchpiguel CA
    Clin Nucl Med; 2013 Apr; 38(4):231-6. PubMed ID: 23429386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of 99mTc-pertechnetate thyroid uptake.
    Reinhardt MJ; Joe A; von Mallek D; Zimmerlin M; Manka-Waluch A; Palmedo H; Krause TM
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):480-5. PubMed ID: 11914885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
    Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves' disease but the total thyroid absorbed dose is not.
    Krohn T; Hänscheid H; Müller B; Behrendt FF; Heinzel A; Mottaghy FM; Verburg FA
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4109-15. PubMed ID: 25033065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
    Breitz HB; Wendt RE; Stabin MS; Shen S; Erwin WD; Rajendran JG; Eary JF; Durack L; Delpassand E; Martin W; Meredith RF
    J Nucl Med; 2006 Mar; 47(3):534-42. PubMed ID: 16513624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncertainties in dose coefficients from ingestion of 131I, 137Cs, and 90Sr.
    Apostoaei AI; Miller LF
    Health Phys; 2004 May; 86(5):460-82. PubMed ID: 15083142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A practical method for the estimation of therapeutic activity in the treatment of Graves' hyperthyroidism.
    Panareo S; Rossi R; Fabbri S; De Paola G; Candini GC; Feggi L; Degli Uberti E
    Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):576-85. PubMed ID: 21068711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.